Category: Investment, Biotech, Biodefense
Biotech Stock News; Wall Street Transcript Interview with Aethlon Medical, Inc. (OTCBB: AEMD) CEO James A. Joyce
Visit this company: www.aethlonmedical.com
67 WALL STREET, New York - August 30, 2012 (Investorideas.com newswire) - The Wall Street Transcript has just published its Medical Research, Diagnostic Substances and Life Science Tools Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Health Care Consolidation Activity - Cost Reduction and Improving Efficiencies - Chinese CRO Growth - NIH Budget Uncertainty
Companies include: Aethlon Medical (AEMD) and many others.
In the following excerpt from the Medical Research, Diagnostic Substances and Life Science Tools Report, the CEO of Aethlon Medical discusses the outlook for his company for investors:
TWST:Would you begin with a brief historical sketch of the company and a picture of its operations at the present time?
Mr. Joyce: I formed Aethlon Medical with the vision that we could create a medical device that would selectively eliminate disease-causing factors from the entire circulatory system, and do so without drug toxicity. I'm proud to say that just over a decade later, we've transformed that vision into a reality. We're now creating medical-device-based therapies to address unmet medical needs in cancer, hepatitis C and other major market disease conditions.
We've also received a contract from the U.S. government to create a device that will reduce the incidence of sepsis, which is often the cause of death in wounded war fighters.
TWST: Please tell us briefly about the science behind these therapies. It sounds as if Aethlon Medical developed numerous products from one platform.
Mr. Joyce: In the beginning, the idea of selectively eliminating hepatitis-C- or cancer-promoting factors from the entire circulatory system was theoretical, at best. However, from a science perspective, we believed that intersecting the capabilities of affinity drug agents with advanced plasma filtration membranes would result in a platform technology that would support our therapeutic objectives. We call this platform the Aethlon ADAPT System, which is an acronym for adaptive dialysis-like affinity platform technology. The ADAPT system allows us to immobilize single or multiple affinity agents within a medical device designed to subtract deleterious targets from circulation versus adding toxic drug agents into circulation.
Our lead product from the ADAPT system is the Aethlon Hemopurifier. The Hemopurifier has demonstrated broad spectrum capabilities against infectious viral pathogens that include bioterror threats, pandemic threats and HIV. In human studies, our primary focus to date has been hepatitis C. We have approximately 100 hepatitis C treatments under our belt, and we've demonstrated that the Hemopurifier can rapidly reduce viral load. We are now preparing to initiate commercialization of the Hemopurifier overseas and anticipate the initiation of human clinical programs in the United States early next year.
We've also discovered that our Hemopurifier is able to capture cancer-secreted exosomes, which are extremely immunosuppressive in cancer patients. Exosomes have also been reported to promote angiogenesis, which is the ability for tumors to create their own blood supply for survival, and in the latest issue of the journal Nature, exosomes were reported to seed the spread of metastasis in cancer patients. That said, exosomes represent a critically important target that can be addressed by our Hemopurifier, yet remain beyond the reach of traditional drug therapies.
TWST: So potentially, there's a gigantic market for these therapies?
For more from this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.